CN104109197B - 一种双识别抗体片段的制备方法及其应用 - Google Patents
一种双识别抗体片段的制备方法及其应用 Download PDFInfo
- Publication number
- CN104109197B CN104109197B CN201310571300.0A CN201310571300A CN104109197B CN 104109197 B CN104109197 B CN 104109197B CN 201310571300 A CN201310571300 A CN 201310571300A CN 104109197 B CN104109197 B CN 104109197B
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- fab
- tracer
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title claims abstract description 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000009977 dual effect Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 claims abstract description 40
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000001514 detection method Methods 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 239000000700 radioactive tracer Substances 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 238000002372 labelling Methods 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 19
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 102000057297 Pepsin A Human genes 0.000 claims description 6
- 108090000284 Pepsin A Proteins 0.000 claims description 6
- 229940111202 pepsin Drugs 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 108010048233 Procalcitonin Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 3
- 238000012384 transportation and delivery Methods 0.000 claims description 3
- LEOJISUPFSWNMA-UHFFFAOYSA-N ABEI Chemical compound O=C1NNC(=O)C=2C1=CC(N(CCCCN)CC)=CC=2 LEOJISUPFSWNMA-UHFFFAOYSA-N 0.000 claims description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 2
- 102000013394 Troponin I Human genes 0.000 claims description 2
- 108010065729 Troponin I Proteins 0.000 claims description 2
- 102000004987 Troponin T Human genes 0.000 claims description 2
- 108090001108 Troponin T Proteins 0.000 claims description 2
- 230000005875 antibody response Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- -1 cerebrospinal fluid Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 238000002965 ELISA Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000012921 fluorescence analysis Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 239000004005 microsphere Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000004816 latex Substances 0.000 description 12
- 229920000126 latex Polymers 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 229940005654 nitrite ion Drugs 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003547 immunosorbent Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007037 hydroformylation reaction Methods 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000004531 microgranule Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Substances [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008086 immune related sensitivity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310571300.0A CN104109197B (zh) | 2013-11-13 | 2013-11-13 | 一种双识别抗体片段的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310571300.0A CN104109197B (zh) | 2013-11-13 | 2013-11-13 | 一种双识别抗体片段的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104109197A CN104109197A (zh) | 2014-10-22 |
CN104109197B true CN104109197B (zh) | 2017-05-10 |
Family
ID=51706200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310571300.0A Active CN104109197B (zh) | 2013-11-13 | 2013-11-13 | 一种双识别抗体片段的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104109197B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105652018A (zh) * | 2016-02-04 | 2016-06-08 | 广州科方生物技术有限公司 | 一种c-肽定量测定试剂盒 |
CN106324251B (zh) * | 2016-08-08 | 2019-03-29 | 上海睿康生物科技有限公司 | 小片段BMG抗体的制备方法及β2-微球蛋白检测试剂盒 |
CN108007989B (zh) * | 2016-10-28 | 2020-04-17 | 中国科学院烟台海岸带研究所 | 基于裂开型多肽为识别分子的检测方法 |
CN110596396B (zh) * | 2019-08-05 | 2022-07-19 | 天津一安生物技术有限公司 | 一种检测蛋白的方法以及试纸条和试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1861708A2 (en) * | 2005-03-08 | 2007-12-05 | Tanox, Inc. | Methods for determining the bivalency of protein and antibody therapeutics |
ES2311423B1 (es) * | 2007-07-27 | 2010-01-07 | Inmunologia Y Genetica Aplicada, S.A. | Inmunoensayo de doble reconocimiento para la deteccion de anticuerpos. |
JP2015507193A (ja) * | 2012-02-01 | 2015-03-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性結合物の結合パートナーを検出するための方法 |
CN103087171B (zh) * | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
-
2013
- 2013-11-13 CN CN201310571300.0A patent/CN104109197B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104109197A (zh) | 2014-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2537873B2 (ja) | 金ゾル試薬の調整方法 | |
CN104109197B (zh) | 一种双识别抗体片段的制备方法及其应用 | |
CN107543932A (zh) | 一种降钙素的磁微粒化学发光检测试剂盒及制备方法 | |
IE20120533A1 (en) | An assay | |
JP7105970B1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット | |
WO2022265065A1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片 | |
US7553676B2 (en) | Specific coupling reaction measuring method | |
CN109564223A (zh) | 肿瘤标记物的测定方法及测定试剂 | |
JP2008014751A (ja) | 着色ラテックス粒子を用いるメンブレンアッセイ法およびキット | |
JP2021520484A (ja) | ラテラルフロー免疫アッセイストリップ装置 | |
JP5104622B2 (ja) | 磁性粒子を用いた測定対象物質の濃度測定法 | |
CN105606803B (zh) | 幽门螺杆菌抗体含量的胶乳增强免疫比浊法试剂盒 | |
CN206038696U (zh) | 一种定量钙卫蛋白检测免疫层析试纸条 | |
Liu et al. | Fluorescent microsphere immunochromatographic assays for detecting bone alkaline phosphatase based on biolayer interferometry-selected antibody | |
JP2014098715A (ja) | 着色ラテックス粒子を用いるメンブレンアッセイ法およびキット | |
JP4578401B2 (ja) | 固定化抗体の製造方法 | |
CN202837303U (zh) | Ngal荧光免疫层析定量检测试纸条 | |
CN107748254A (zh) | 一种n‑端脑利钠肽前体检测试剂盒及其应用 | |
WO1987002780A1 (en) | Method of immunoassay | |
TW202219509A (zh) | 改善訊號降低之檢查試劑 | |
JPH038512B2 (zh) | ||
JPH02503951A (ja) | アッセイ | |
JPS6228666A (ja) | 生物学的試料中の抗原及び抗体検出法及び検出用支持体 | |
JP2017036917A (ja) | ヘリコバクター・ピロリの検出方法 | |
US6939681B1 (en) | Method of detecting an antibody in a liquid sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Ye Sen Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Ye Sen Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201029 Address after: 197 Yaogu Avenue, Jiangbei new district, Nanjing, Jiangsu Province Patentee after: NANJING NORMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 210000 building E, building 10, Spark Road, Pukou hi tech Development Zone, Nanjing, Jiangsu Patentee before: Ye Sen |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No.197, Yaogu Avenue, Jiangbei new district, Nanjing City, Jiangsu Province Patentee after: Nanjing Norman Biotechnology Co.,Ltd. Address before: 197 Yaogu Avenue, Jiangbei new district, Nanjing, Jiangsu Province Patentee before: NANJING NORMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20141022 Assignee: Nanjing Jiangbei new area Yangzi Technology Finance Leasing Co.,Ltd. Assignor: Nanjing Norman Biotechnology Co.,Ltd. Contract record no.: X2021320000066 Denomination of invention: A preparation method of double recognition antibody fragment and its application Granted publication date: 20170510 License type: Exclusive License Record date: 20210805 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of double recognition antibody fragment and its application Effective date of registration: 20210811 Granted publication date: 20170510 Pledgee: Nanjing Jiangbei new area green Financing Guarantee Co.,Ltd. Pledgor: Nanjing Norman Biotechnology Co.,Ltd. Registration number: Y2021320000166 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Nanjing Jiangbei new area Yangzi Technology Finance Leasing Co.,Ltd. Assignor: Nanjing Norman Biotechnology Co.,Ltd. Contract record no.: X2021320000066 Date of cancellation: 20220909 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220908 Granted publication date: 20170510 Pledgee: Nanjing Jiangbei new area green Financing Guarantee Co.,Ltd. Pledgor: Nanjing Norman Biotechnology Co.,Ltd. Registration number: Y2021320000166 |